Skip to main content
Fig. 7 | BMC Cancer

Fig. 7

From: Integrated analysis of the relation to tumor immune microenvironment and predicted value of Stonin1 gene for immune checkpoint blockage and targeted treatment in kidney renal clear cell carcinoma

Fig. 7

The different immune phenotypes between the low and high STON1 groups. A Enrichment score of cancer-immunity cycle steps between the two groups. (High, high expression of the STON1 group; low, low expression of the STON1 group; ssGSEA analysis and the Wilcoxon test; the abscissa represents different anti-tumor immune cycle steps and the ordinate represents the enrichment score based on special gene signatures; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not statistically significant). B The correlation between STON1 expression and the enrichment score of cancer-immunity cycle. C Enrichment score of four stromal pathways between the two groups. (High, high expression of STON1 group; low, low expression of STON1 group; GSVA analysis and the Wilcoxon test; **P < 0.01; ****P <0.0001; ns, not statistically significant)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us